Brokerages Set Omeros Corporation (NASDAQ:OMER) Price Target at $18.00

Key Points

• Omeros Corporation has a consensus rating of "Moderate Buy" from six brokerages, with two hold recommendations, three buy recommendations, and one strong buy recommendation.
• The average 12-month price target for Omeros' stock among analysts is $18.00, despite recent downgrades from some research firms.
• Omeros' stock opened at $3.70, with a market capitalization of $228.51 million and a 1-year low of $2.95.

Shares of Omeros Corporation (NASDAQ:OMER - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Two research analysts have rated the stock with a hold rating, three have assigned a buy rating and one has issued a strong buy rating on the company. The average 1-year price target among brokerages that have issued a report on the stock in the last year is $18.00.

OMER has been the subject of a number of research reports. D. Boral Capital reiterated a "buy" rating and issued a $36.00 price objective on shares of Omeros in a research report on Friday, July 25th. Needham & Company LLC reaffirmed a "hold" rating on shares of Omeros in a research note on Friday, May 16th. HC Wainwright reissued a "buy" rating and set a $9.00 price target on shares of Omeros in a research note on Friday, June 27th. Finally, Wall Street Zen lowered shares of Omeros from a "hold" rating to a "sell" rating in a report on Friday, June 27th.

Omeros Price Performance

Shares of OMER stock traded up $0.21 during trading hours on Tuesday, reaching $3.99. 528,059 shares of the company were exchanged, compared to its average volume of 890,592. Omeros has a fifty-two week low of $2.95 and a fifty-two week high of $13.60. The stock's fifty day moving average is $3.49 and its two-hundred day moving average is $5.99. The company has a market cap of $246.11 million, a price-to-earnings ratio of -1.49 and a beta of 2.26.

Omeros (NASDAQ:OMER - Get Free Report) last announced its quarterly earnings data on Thursday, May 15th. The biopharmaceutical company reported ($0.65) EPS for the quarter, missing analysts' consensus estimates of ($0.60) by ($0.05). On average, research analysts anticipate that Omeros will post -3.09 earnings per share for the current year.

Institutional Trading of Omeros

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Nomura Holdings Inc. grew its holdings in Omeros by 136.2% during the fourth quarter. Nomura Holdings Inc. now owns 747,281 shares of the biopharmaceutical company's stock valued at $7,383,000 after purchasing an additional 430,932 shares during the period. Susquehanna Fundamental Investments LLC bought a new stake in shares of Omeros in the 4th quarter valued at $1,488,000. Wellington Management Group LLP acquired a new stake in Omeros during the 1st quarter worth $1,118,000. Nuveen LLC bought a new position in Omeros during the first quarter worth about $938,000. Finally, Jacobs Levy Equity Management Inc. acquired a new position in Omeros in the fourth quarter valued at about $1,033,000. 48.79% of the stock is owned by institutional investors.

Omeros Company Profile

Omeros Corporation, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting immunologic diseases, including complement-mediated diseases, cancers, and addictive and compulsive disorders. The company's products under development include Narsoplimab (OMS721/MASP-2) that has completed pivotal trial for hematopoietic stem-cell transplant-associated thrombotic microangiopathy (TA-TMA); that is in Phase III clinical trial for the treatment of immunoglobulin A nephropathy (IgAN); and Phase II clinical trial to treat COVID-19.